Want to join the conversation?
Predictive analytics solutions provider $VRSK said its 4Q15 results were in line with expectations with an increase in diluted adjusted EPS of about 23%. Full year revenue grew 18% and diluted adjusted EPS rose about 29%. $VRSK grew the topline, excluding the Healthcare Analytics business and recent acquisitions, over 5% in 4Q15 and 7% in 2015.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.